home / stock / lptx / lptx quote
Last: | $2.63 |
---|---|
Change Percent: | -1.09% |
Open: | $2.77 |
Close: | $2.63 |
High: | $2.77 |
Low: | $2.57 |
Volume: | 375,786 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.63 | $2.77 | $2.63 | $2.77 | $2.57 | 375,786 | 05-17-2024 |
$2.74 | $2.8 | $2.74 | $2.8 | $2.71 | 133,635 | 05-16-2024 |
$2.8 | $2.8 | $2.8 | $2.92 | $2.74 | 298,523 | 05-15-2024 |
$2.75 | $2.86 | $2.75 | $3 | $2.72 | 247,881 | 05-14-2024 |
$2.83 | $2.76 | $2.83 | $2.99 | $2.71 | 205,944 | 05-13-2024 |
$2.78 | $2.91 | $2.78 | $2.9799 | $2.72 | 125,413 | 05-10-2024 |
$2.91 | $3 | $2.91 | $3.01 | $2.85 | 146,980 | 05-09-2024 |
$2.99 | $3.07 | $2.99 | $3.1192 | $2.91 | 161,377 | 05-08-2024 |
$3.07 | $3.23 | $3.07 | $3.2899 | $3.05 | 207,494 | 05-07-2024 |
$3.22 | $3.19 | $3.22 | $3.26 | $3.05 | 238,381 | 05-06-2024 |
$3.19 | $3.27 | $3.19 | $3.28 | $3.01 | 334,593 | 05-03-2024 |
$3.17 | $3.31 | $3.17 | $3.35 | $3.05 | 137,458 | 05-02-2024 |
$3.27 | $3.14 | $3.27 | $3.29 | $3.11 | 151,390 | 05-01-2024 |
$3.1 | $3.07 | $3.1 | $3.2889 | $3.0176 | 105,872 | 04-30-2024 |
$3.07 | $3.26 | $3.07 | $3.3999 | $3.03 | 130,420 | 04-29-2024 |
$3.25 | $3.29 | $3.25 | $3.39 | $2.99 | 403,202 | 04-26-2024 |
$3.17 | $3.19 | $3.17 | $3.29 | $3.11 | 213,233 | 04-25-2024 |
$3.29 | $3.2 | $3.29 | $3.3 | $3.1 | 193,824 | 04-24-2024 |
$3.2 | $3.21 | $3.2 | $3.33 | $3.09 | 89,018 | 04-23-2024 |
$3.21 | $2.86 | $3.21 | $3.26 | $2.85 | 328,700 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...